)
)
Cassava Sciences Investor Relations Material
Latest events
Status Update
Cassava Sciences
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Cassava Sciences Inc
Access all reports
Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for neurodegenerative diseases, with a primary focus on Alzheimer’s disease. The company’s leading drug candidate, simufilam, is an oral small molecule in 3 clinical trials aimed at treating Alzheimer’s by targeting an altered form of a brain protein known as filamin A. Cassava Sciences is also developing SavaDx, an investigational diagnostic tool designed to detect Alzheimer's disease through a blood test. The company is headquartered in Austin, Texas, and its shares are listed on the NASDAQ.
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
SAVA
Country
🇺🇸 United States